335 related articles for article (PubMed ID: 25646357)
1. A randomized controlled Phase III trial comparing 2-weekly docetaxel combined with cisplatin plus fluorouracil (2-weekly DCF) with cisplatin plus fluorouracil (CF) in patients with metastatic or recurrent esophageal cancer: rationale, design and methods of Japan Clinical Oncology Group study JCOG1314 (MIRACLE study).
Kataoka K; Tsushima T; Mizusawa J; Hironaka S; Tsubosa Y; Kii T; Shibuya Y; Chin K; Katayama H; Kato K; Fukuda H; Kitagawa Y;
Jpn J Clin Oncol; 2015 May; 45(5):494-8. PubMed ID: 25646357
[TBL] [Abstract][Full Text] [Related]
2. Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study).
Nakamura K; Kato K; Igaki H; Ito Y; Mizusawa J; Ando N; Udagawa H; Tsubosa Y; Daiko H; Hironaka S; Fukuda H; Kitagawa Y;
Jpn J Clin Oncol; 2013 Jul; 43(7):752-5. PubMed ID: 23625063
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807).
Hironaka S; Tsubosa Y; Mizusawa J; Kii T; Kato K; Tsushima T; Chin K; Tomori A; Okuno T; Taniki T; Ura T; Matsushita H; Kojima T; Doki Y; Kusaba H; Fujitani K; Taira K; Seki S; Nakamura T; Kitagawa Y;
Cancer Sci; 2014 Sep; 105(9):1189-95. PubMed ID: 25041052
[TBL] [Abstract][Full Text] [Related]
4. Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003).
Yamasaki M; Yasuda T; Yano M; Hirao M; Kobayashi K; Fujitani K; Tamura S; Kimura Y; Miyata H; Motoori M; Shiraishi O; Makino T; Satoh T; Mori M; Doki Y
Ann Oncol; 2017 Jan; 28(1):116-120. PubMed ID: 27687307
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus.
Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Matsumura S; Iwahashi M; Yamaue H
Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 26725778
[TBL] [Abstract][Full Text] [Related]
6. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group.
Ajani JA; Moiseyenko VM; Tjulandin S; Majlis A; Constenla M; Boni C; Rodrigues A; Fodor M; Chao Y; Voznyi E; Awad L; Van Cutsem E;
J Clin Oncol; 2007 Aug; 25(22):3210-6. PubMed ID: 17664468
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus.
Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Kato T; Kitadani J; Tabata H; Takeuchi A; Iwahashi M; Yamaue H
Anticancer Res; 2016 Feb; 36(2):829-34. PubMed ID: 26851048
[TBL] [Abstract][Full Text] [Related]
8. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Van Cutsem E; Moiseyenko VM; Tjulandin S; Majlis A; Constenla M; Boni C; Rodrigues A; Fodor M; Chao Y; Voznyi E; Risse ML; Ajani JA;
J Clin Oncol; 2006 Nov; 24(31):4991-7. PubMed ID: 17075117
[TBL] [Abstract][Full Text] [Related]
9. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group.
Ajani JA; Moiseyenko VM; Tjulandin S; Majlis A; Constenla M; Boni C; Rodrigues A; Fodor M; Chao Y; Voznyi E; Marabotti C; Van Cutsem E;
J Clin Oncol; 2007 Aug; 25(22):3205-9. PubMed ID: 17664467
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma.
Miyawaki Y; Nakajima Y; Kawada K; Okada T; Tokairin Y; Kawano T
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27001629
[TBL] [Abstract][Full Text] [Related]
11. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer.
Wang J; Xu R; Li J; Bai Y; Liu T; Jiao S; Dai G; Xu J; Liu Y; Fan N; Shu Y; Ba Y; Ma D; Qin S; Zheng L; Chen W; Shen L
Gastric Cancer; 2016 Jan; 19(1):234-44. PubMed ID: 25604851
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma.
Tanaka Y; Yoshida K; Yamada A; Tanahashi T; Okumura N; Matsuhashi N; Yamaguchi K; Miyazaki T
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1143-52. PubMed ID: 26896963
[TBL] [Abstract][Full Text] [Related]
13. Comparison of preoperative chemotherapy using docetaxel, cisplatin and fluorouracil with cisplatin and fluorouracil in patients with advanced carcinoma of the thoracic esophagus.
Ui T; Fujii H; Hosoya Y; Nagase M; Mieno MN; Mori M; Zuiki T; Saito S; Kurashina K; Haruta H; Matsumoto S; Niki T; Lefor A; Yasuda Y
Dis Esophagus; 2015; 28(2):180-7. PubMed ID: 24529073
[TBL] [Abstract][Full Text] [Related]
14. Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysis.
Nomura M; Oze I; Abe T; Komori A; Narita Y; Masuishi T; Taniguchi H; Kadowaki S; Ura T; Andoh M; Kawai R; Uemura N; Ishihara M; Tanaka T; Tajika M; Niwa Y; Muro K; Muto M
Cancer Chemother Pharmacol; 2015 Aug; 76(2):357-63. PubMed ID: 26092324
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence.
Yamashita K; Hosoda K; Moriya H; Katada C; Sugawara M; Mieno H; Komori S; Katada N; Watanabe M
Oncology; 2017; 92(4):221-228. PubMed ID: 28110330
[TBL] [Abstract][Full Text] [Related]
16. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer.
Overman MJ; Kazmi SM; Jhamb J; Lin E; Yao JC; Abbruzzese JL; Ho L; Ajani J; Phan A
Cancer; 2010 Mar; 116(6):1446-53. PubMed ID: 20108336
[TBL] [Abstract][Full Text] [Related]
17. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma.
Ajani JA; Fodor MB; Tjulandin SA; Moiseyenko VM; Chao Y; Cabral Filho S; Majlis A; Assadourian S; Van Cutsem E
J Clin Oncol; 2005 Aug; 23(24):5660-7. PubMed ID: 16110025
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
Kim S; Jary M; André T; Vendrely V; Buecher B; François E; Bidard FC; Dumont S; Samalin E; Peiffert D; Pernot S; Baba-Hamed N; El Hajbi F; Bouché O; Desrame J; Parzy A; Zoubir M; Louvet C; Bachet JB; Nguyen T; Abdelghani MB; Smith D; De La Fouchardière C; Aparicio T; Bennouna J; Gornet JM; Jacquin M; Bonnetain F; Borg C
BMC Cancer; 2017 Aug; 17(1):574. PubMed ID: 28841909
[TBL] [Abstract][Full Text] [Related]
19. Investigation of operative outcomes of thoracoscopic esophagectomy after triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for advanced esophageal squamous cell carcinoma.
Akiyama Y; Iwaya T; Endo F; Chiba T; Takahara T; Otsuka K; Nitta H; Koeda K; Mizuno M; Kimura Y; Sasaki A
Surg Endosc; 2018 Jan; 32(1):391-399. PubMed ID: 28664431
[TBL] [Abstract][Full Text] [Related]
20. A Phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206).
Eba J; Kenmotsu H; Tsuboi M; Niho S; Katayama H; Shibata T; Watanabe S; Yamamoto N; Tamura T; Asamura H; ;
Jpn J Clin Oncol; 2014 Apr; 44(4):379-82. PubMed ID: 24474818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
